Alcon Inc. (ALC)
| Market Cap | 38.21B |
| Revenue (ttm) | 10.19B |
| Net Income (ttm) | 1.05B |
| Shares Out | 491.20M |
| EPS (ttm) | 2.10 |
| PE Ratio | 36.49 |
| Forward PE | 23.12 |
| Dividend | $0.22 (0.28%) |
| Ex-Dividend Date | May 14, 2025 |
| Volume | 2,642,705 |
| Open | 77.86 |
| Previous Close | 78.61 |
| Day's Range | 77.41 - 78.32 |
| 52-Week Range | 71.55 - 99.20 |
| Beta | 0.69 |
| Analysts | Buy |
| Price Target | 89.96 (+15.85%) |
| Earnings Date | Nov 11, 2025 |
About ALC
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]
Financial Performance
In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ALC stock is "Buy." The 12-month stock price target is $89.96, which is an increase of 15.85% from the latest price.
News
Alcon: Some Premium Coming Out Of This Quality Play
Alcon Inc. remains a global leader in eye care, benefiting from aging demographics and technological innovation, but faces valuation and growth headwinds. Recent M&A activity, including the pending ST...
Alcon Inc. (ALC) Q3 2025 Earnings Call Transcript
Alcon Inc. ( ALC) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Daniel Cravens - Vice President of Investor Relations David Endicott - CEO & Director Timothy Stonesifer - S...
New Eye Tech Is Booming For Alcon, Stock Soars
Eye care firm Alcon Inc. (NYSE:ALC) on Tuesday reported third-quarter sales of $2.59 billion, up 6% year over year (up 5% constant currency), marginally missing the consensus of $2.60 billion.
Alcon Shares in Switzerland Climb After Guidance Confirmation
Shares rose after the eye-care specialist reported an acceleration in sales growth and confirmed its annual outlook, reassuring on its prospects after two guidance cuts this year.
Invesco Diversified Dividend Fund Q3 2025 Portfolio Positioning
Dupont (DD) is a leading specialty chemical company in the process of spinning off its electronics business, which in our view should unlock shareholder value. KKR (KKR) is a leading private equity in...
Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds
GENEVA--(BUSINESS WIRE)--Alcon Delivers Solid Third-Quarter 2025 Results with Accelerated Growth in Equipment and Ocular Health; Unity VCS Momentum Builds.
Virtus SGA International Growth Q3 2025 Contributors And Detractors
Alibaba was a contributor to the portfolio during the quarter, driven by strong execution in its core commerce and cloud businesses, and improved investor sentiment around management's strategic direc...
Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today commented on the recent filing of amendments to the merger agreement in connection with the pro...
STAAR Surgical Announces Amendments to Alcon Merger Agreement
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Broadwood Partners Condemns Alcon's Fallacious Attacks on STAAR Surgical and Its Prospects
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the investor presentation issued by Alcon Inc. (“Alcon”) (NYSE: ALC) regarding its propo...
Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
GENEVA--(BUSINESS WIRE)--Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders.
Aristotle Global Equity Advisory Q3 2025 Contributors And Detractors
MonotaRO, the Japanese business-to-business (B2B) e-commerce platform, was the largest detractor during the quarter. Pawn shop operator FirstCash was the top contributor during the quarter. Aggregates...
Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company...
Harding Loevner International Equity ADR Q3 2025 Portfolio Update
The International Equity ADR composite rose 3.0% gross of fees in the second quarter, behind the 7.0% gain of the MSCI ACWI ex US Index. In Communication Services, Tencent delivered a second consecuti...
STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) announced that, in light of ongoing discussions with Alcon (SIX/NY...
Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company...
Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which owns 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NAS...
Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufact...
Yunqi Capital Issues Letter to STAAR Surgical's Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company...
Broadwood Partners Highlights Growing Opposition to STAAR Surgical's Proposed Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the increasing public opposition to the proposed acquisition of STAAR Surgical Company (...
Broadwood Partners Issues Letter to STAAR Surgical's Board Urging it to Allow Timely Shareholder Vote on Alcon Sale
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (...
Broadwood Partners: All Three Leading Proxy Advisory Firms Recommend STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy advisory ...
Broadwood Partners Comments on STAAR Surgical's Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the recent Current Report on Form 8-K filed by STAAR Surgical Company (“STAAR” or the “C...
Broadwood Partners Issues Letter to STAAR Surgical's Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (...
STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correc...